The World’s Smallest Hero! Epeius Bio’s Rexin-G, Targeted Therapy for Metastatic Cancers

SAN MARINO, Calif. — Epeius Biotechnologies’ Rexin-G® is the world’s smallest hero (epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside.

Guided by nature’s own disease-seeking factors (i.e., pathotropic targeting), armed with a powerful tumor-killing designer gene, and trained in the art of efficient gene delivery over aeons of evolutionary engineering, these tiny therapeutic particles represent a new paradigm in drug delivery and a new class of anti-cancer agents that exhibit profound and unprecedented single-agent efficacy in many cancers.

By selectively targeting cancers and their associated blood supply, while sparing normal cells and healthy tissues, these tiny nano-particles are inherently “smart.” In performing a vital cancer surveillance function, they are uniformly “vigilant.” By taking on a broad spectrum of cancers that are determined to be refractory to standard chemotherapy (i.e., ineffectual apothecary), they are exceedingly “valiant.”

By reducing the cancer patient’s body burden and extending overall survival, they are truly “heroic.” In a manner of speaking, these tiny nano-particles may well be the smallest heroes in all the world.

These “heroic” qualities are now embodied in the tumor-targeted anti-cancer agent, Rexin-G, developed by Epeius Biotechnologies. Rexin-G is currently approved for the treatment of all solid chemo-resistant tumors in the Republic of the Philippines. It has recently been granted Orphan Drug Status and market protections for three separate cancer indications by the U.S. FDA. Ongoing clinical trials in the U.S. have established the thresholds for bioactivity and the dose-dependent efficacy of Rexin-G, as well as its overall safety and lack of any dose-limiting toxicity.

Recent advanced and confirmatory clinical trials in the U.S. have demonstrated single-agent efficacy, which included both progression-free survival and overall survival. Not bad, for the world’s smallest unsung hero.

For further information about Rexin-G, high-performance targeting technologies, and/or new products in development, see www.epeiusbiotech.com. For further information about current clinical trials, contact Erlinda M. Gordon, M.D., at egordon @ epeiusbiotech.com.

About Aria Munro

ABOUT THE EDITOR: Aria C. Munro works in the book publishing industry and has been a content editor for the Neotrope News Network since 2004. Her black video iPod is most often shuffling Invader Zim episode vids and Thomas Dolby or Dead Can Dance tunez.

Web | More Posts (3942)

• Epeius’ Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
• Epeius Biotech Reports Dose-Dependent Efficacy and Survival Benefits, Efficacy of Rexin-G in Metastatic Pancreas Cancer
• Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy
• Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
• Epeius Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
• Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
• REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
• Epeius Bio’s Rexin-G® Receives High-tech Validation as Strategic Anti-cancer Agent

Comments are closed for this story, sorry. Please provide any feedback to the company(s) mentioned in the above story or press release.